Latozinemab by Alector for Frontotemporal Dementia (FTD): Likelihood of Approval
Latozinemab is under clinical development by Alector and currently in Phase III for Frontotemporal Dementia (FTD). According to GlobalData, Phase III drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Latozinemab LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Latozinemab overviewlatozinemab is under development for the treatment of frontotemporal dementia (FTD) (with progranulin mutation (FTD-GRN) and with a C9orf72 mutation (FTD-C9orf72)). It is administered through an intravenous route. The drug candidate acts by targeting sortilin (SORT1). It was under development for amyotrophic lateral sclerosis (ALS).Alector overviewAlector is a biotechnology company that develops therapies for the immune system to cure neurodegeneration and cancer. The company discovers and develops immune-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. It combines state-of-the-art antibody technology and recent discoveries in neuroimmunology and oncology to fight cancer. Alector also generates and validates antibody drugs that are into disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. Alector is headquartered in South San Francisco, California, the US. For a complete picture of Latozinemab's drug-specific PTSR and LoA scores, buy the report here.
Latozinemab is under clinical development by Alector and currently in Phase III for Frontotemporal Dementia (FTD).
What's Your Reaction?
